All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
On April 1, 2022, it was announced that the U.S. Food and Drug Administration (FDA) had granted approval to the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) for adult patients with large B-cell lymphoma (LBCL) who have relapsed within 12 months of, or who are refractory to, first-line chemoimmunotherapy.1 This change in authorization could expand the pool of those eligible for CAR T-cell therapy by up to 11,000 patients in the U.S. alone.1 LBCL is the most commonly diagnosed form of non-Hodgkin lymphoma globally.2
The approval is based on key data obtained from the ZUMA-7 trial.
This approval could help to address an area of unmet need for patients with LBCL who do not respond well to high-dose chemoimmunotherapy.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox